Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Revelation Biosciences (NASDAQ: REVB) announced FDA acceptance of its investigational new drug (IND) application for Gemini. The company will initiate a US-based Phase 1b clinical study to evaluate Gemini as a preconditioning treatment in chronic kidney disease (CKD) patients. The study will enroll up to 40 subjects across 5 cohorts, focusing on safety and tolerability of a single Gemini dose. Positive results would enable a Phase 2 study targeting the reduction of acute kidney injury in patients undergoing coronary artery bypass graft and cardiac valve surgery.
Revelation Biosciences (NASDAQ: REVB) ha annunciato l'accettazione da parte della FDA della sua domanda di nuovo farmaco investigativo (IND) per Gemini. L'azienda avvier脿 uno studio clinico di Fase 1b negli Stati Uniti per valutare Gemini come trattamento precondizionante nei pazienti con malattia renale cronica (CKD). Lo studio recluter脿 fino a 40 soggetti distribuiti in 5 coorti, concentrandosi sulla sicurezza e tollerabilit脿 di una singola dose di Gemini. Risultati positivi consentirebbero l'avvio di uno studio di Fase 2 mirato alla riduzione dell'infortunio renale acuto nei pazienti sottoposti a bypass coronarico e interventi di sostituzione valvolare cardiaca.
Revelation Biosciences (NASDAQ: REVB) anunci贸 la aceptaci贸n por parte de la FDA de su solicitud de nuevo f谩rmaco en investigaci贸n (IND) para Gemini. La compa帽铆a iniciar谩 un estudio cl铆nico de Fase 1b en EE.UU. para evaluar a Gemini como tratamiento de precondicionamiento en pacientes con enfermedad renal cr贸nica (CKD). El estudio incluir谩 hasta 40 sujetos distribuidos en 5 cohortes, enfoc谩ndose en la seguridad y tolerabilidad de una sola dosis de Gemini. Resultados positivos permitir铆an el lanzamiento de un estudio de Fase 2 enfocado en la reducci贸n de lesiones renales agudas en pacientes que se someten a cirug铆a de bypass de arteria coronaria y cirug铆a de v谩lvula card铆aca.
霠堧波霠堨澊靺� 氚旍澊鞓れ偓鞚挫柛鞀� (NASDAQ: REVB)電� 鞝滊雼�鞐� 雽�頃� FDA鞚� 鞁犾暯 鞛勳儊鞁滍棙 鞀轨澑(IND) 靾橂澖鞚� 氚滍憸頄堨姷雼堧嫟. 鞚� 須岇偓電� 毵岇劚 鞁犾灔 歆堩櫂(CKD) 頇橃瀽鞐愳劀 鞝滊雼堧ゼ 鞝勳矘旃� 旃橂搿� 韽夑皜頃橁赴 鞙勴暣 氙戈淡鞐愳劀 1b靸� 鞛勳儊 鞐瓣惮毳� 鞁滌瀾頃� 鞓堨爼鞛呺媹雼�. 鞚� 鞐瓣惮電� 5臧滌潣 歆戨嫧鞐愳劀 斓滊寑 40氇呾潉 韽暔頃橃棳 雼澕 鞝滊雼� 韴棳霟夓潣 鞎堨爠靹标臣 雮挫暯靹膘潉 欷戩爯鞝侅溂搿� 臁办偓頃╇媹雼�. 旮嶌爼鞝侅澑 瓴瓣臣電� 甏�靸� 霃欕Д 鞖绊殞 靾橃垹 氚� 鞁灔 韺愲 靾橃垹鞚� 氚涬姅 頇橃瀽鞐愳劀 旮夓劚 鞁犾啇靸侅潉 欷勳澊電� 瓴冹潉 氇╉憸搿� 頃橂姅 2靸� 鞐瓣惮 歆勴枆鞚� 臧�電ロ晿瓴� 頃� 瓴冹瀰雼堧嫟.
Revelation Biosciences (NASDAQ: REVB) a annonc茅 l'acceptation par la FDA de sa demande de nouveau m茅dicament exp茅rimental (IND) pour Gemini. L'entreprise va lancer une 茅tude clinique de Phase 1b bas茅e aux 脡tats-Unis pour 茅valuer Gemini en tant que traitement de pr茅conditionnement chez les patients atteints de maladie r茅nale chronique (CKD). L'茅tude recrutera jusqu'脿 40 sujets r茅partis en 5 cohortes, en se concentrant sur la s茅curit茅 et la tol茅rance d'une seule dose de Gemini. Des r茅sultats positifs permettraient de mener une 茅tude de Phase 2 visant 脿 r茅duire les l茅sions r茅nales aigu毛s chez les patients subissant une chirurgie de pontage coronarien et une chirurgie de remplacement de valve cardiaque.
Revelation Biosciences (NASDAQ: REVB) hat die Akzeptanz des FDA-Antrags f眉r ein neues investigational Medikament (IND) f眉r Gemini bekannt gegeben. Das Unternehmen wird eine Phase 1b klinische Studie in den USA starten, um Gemini als Vorbehandlung bei Patienten mit chronischer Nierenerkrankung (CKD) zu evaluieren. Die Studie wird bis zu 40 Teilnehmer in 5 Kohorten einschlie脽en, wobei der Fokus auf der Sicherheit und Vertr盲glichkeit einer einzigen Dosis von Gemini liegt. Positive Ergebnisse w眉rden eine Phase 2 Studie erm枚glichen, die auf die Verringerung akuter Nierenverletzungen bei Patienten abzielt, die sich einer koronaren Bypass-Operation und Herzklappenoperation unterziehen.
- FDA acceptance of IND application for Gemini
- Advancement to Phase 1b clinical trials
- Clear pathway to Phase 2 studies pending positive results
- Study not expected to begin until early 2025
- initial study size of only 40 subjects
Insights
The FDA's acceptance of the IND for Gemini represents a significant regulatory milestone, enabling clinical trials in CKD patients. The Phase 1b study design with 40 subjects across 5 cohorts is relatively small but appropriate for initial safety assessment. The focus on preconditioning treatment for CKD patients undergoing cardiac surgery addresses a significant unmet medical need, as AKI is a common complication in this population.
The study's biomarker-driven approach to measure immune response modulation shows scientific rigor, though actual efficacy signals won't be clear until Phase 2. With a
-Phase 1b Study in CKD Patients to begin early 2025-
The multi-site, placebo-controlled Phase 1b clinical study will enroll up to 40 subjects in up to 5 cohorts. The primary endpoint is evaluation of the safety and tolerability of a single dose of Gemini in patients with CKD. Secondary and exploratory endpoints will assess the pharmacokinetics, and the potential of Gemini to mobilize and attenuate the innate immune response to stress by measuring several predictive biomarkers of efficacy.
Positive data from the Phase 1b study will enable a Phase 2 study of Gemini as a preconditioning treatment in patients with CKD to reduce the incidence, duration, and severity of acute kidney injury (AKI) in patients undergoing coronary artery bypass graft (CABG) and/or cardiac valve surgery.
鈥淲e are proud to receive acceptance of our IND for Gemini, marking our most important milestone to date for Revelation,鈥� said , Chief Executive Officer of Revelation. 鈥淏y leveraging the unique properties of trained immunity, we are exploring new ways to improve patient outcomes. We will continue to move swiftly to initiate our Phase 1b clinical study in the near future.鈥�
For more information on Revelation, please visit .
About Gemini
Gemini is an intravenously administrated, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD庐) that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress (surgery, trauma, infection, etc.) in an attenuated manner. Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Earlier this year Revelation announced positive Phase 1 clinical data for intravenous treatment with Gemini. The primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity as observed through expected changes in multiple biomarkers including upregulation of IL-10.
Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program). In addition, Gemini has potential as a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program).
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for acute kidney injury, as a prevention for post-surgical infection, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit .
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management鈥檚 expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation鈥檚 product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation鈥檚 balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
View source version on businesswire.com:
Company Contacts
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
Source: Revelation Biosciences, Inc.
FAQ
When will Revelation Biosciences (REVB) begin its Phase 1b study for Gemini?
How many patients will be enrolled in Revelation Biosciences' (REVB) Gemini Phase 1b trial?
What is the primary endpoint of REVB's Gemini Phase 1b study?
What is the potential therapeutic application for Revelation's (REVB) Gemini in Phase 2?
